1. Home
  2. GBIO vs CMCM Comparison

GBIO vs CMCM Comparison

Compare GBIO & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • CMCM
  • Stock Information
  • Founded
  • GBIO 2016
  • CMCM 2009
  • Country
  • GBIO United States
  • CMCM China
  • Employees
  • GBIO N/A
  • CMCM N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • GBIO Health Care
  • CMCM Technology
  • Exchange
  • GBIO Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • GBIO 165.5M
  • CMCM 132.7M
  • IPO Year
  • GBIO 2020
  • CMCM 2014
  • Fundamental
  • Price
  • GBIO $1.37
  • CMCM $4.42
  • Analyst Decision
  • GBIO Strong Buy
  • CMCM
  • Analyst Count
  • GBIO 2
  • CMCM 0
  • Target Price
  • GBIO $7.50
  • CMCM N/A
  • AVG Volume (30 Days)
  • GBIO 179.9K
  • CMCM 22.9K
  • Earning Date
  • GBIO 11-06-2024
  • CMCM 11-29-2024
  • Dividend Yield
  • GBIO N/A
  • CMCM N/A
  • EPS Growth
  • GBIO N/A
  • CMCM N/A
  • EPS
  • GBIO N/A
  • CMCM N/A
  • Revenue
  • GBIO $18,582,000.00
  • CMCM $97,678,928.00
  • Revenue This Year
  • GBIO $188.06
  • CMCM N/A
  • Revenue Next Year
  • GBIO N/A
  • CMCM N/A
  • P/E Ratio
  • GBIO N/A
  • CMCM N/A
  • Revenue Growth
  • GBIO 514.08
  • CMCM N/A
  • 52 Week Low
  • GBIO $1.10
  • CMCM $1.87
  • 52 Week High
  • GBIO $4.65
  • CMCM $6.78
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 26.45
  • CMCM 50.86
  • Support Level
  • GBIO $1.24
  • CMCM $4.00
  • Resistance Level
  • GBIO $2.57
  • CMCM $4.80
  • Average True Range (ATR)
  • GBIO 0.21
  • CMCM 0.25
  • MACD
  • GBIO -0.07
  • CMCM 0.00
  • Stochastic Oscillator
  • GBIO 9.77
  • CMCM 46.55

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: